Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31, 2025. In a presentation at the 43rd Annual J.P.

Investing.com - The Japanese yen has been on the rise of late, boosted by the dip in US Treasury yields, and Capital ...

Global Equities Research analyst Trip Chowdhry has highlighted potential demand issues for Tesla (NASDAQ: TSLA)’s Cybertruck ...

Shares of Texas Instruments (NASDAQ:TXN) and Analog Devices (NASDAQ:ADI) declined 4% and 2% respectively, as China begins an ...

The transaction with Infinidat is expected to create strategic synergies with Lenovo’s infrastructure solutions business and enterprise storage capabilities. With Infinidat’s strong storage solutions ...

A polar vortex is expected to cause temperatures to fall below freezing across most of the United States starting this ...

UBS downgraded Saint Gobain (EPA: SGOB) to Neutral from Buy in a note Thursday, citing limited upside potential following a ...

Jefferies maintains a buy rating on both International Paper and Packaging Corp of America, signaling confidence in their market positions and financial outlooks. This positive outlook is based on the ...

As the bull market enters its third year, the Sevens Report sees little reason for bearishness despite stretched valuations ...

Investing.com -- Analysts at RBC Capital Markets have initiated coverage on two Spanish banks, Bankinter (BME: BKT) and ...

Goldman Sachs analysts cut Nokia (HE: NOKIA) stock rating to Sell from Neutral in a move largely based on valuation concerns ...

Shares of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) tumbled 51% after the company disclosed receiving a Complete Response Letter (CRL) from the U.S. Food and Dru ...